466 related articles for article (PubMed ID: 26375889)
1. A critical assessment of the scientific basis, and implementation, of regulations for the safety assessment and marketing of innovative tobacco-related products.
Combes RD; Balls M
Altern Lab Anim; 2015 Sep; 43(4):251-90. PubMed ID: 26375889
[TBL] [Abstract][Full Text] [Related]
2. No sisyphean task: how the FDA can regulate electronic cigarettes.
Paradise J
Yale J Health Policy Law Ethics; 2013; 13(2):326-74. PubMed ID: 24340824
[TBL] [Abstract][Full Text] [Related]
3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
4. In vitro exposure systems and dosimetry assessment tools for inhaled tobacco products: Workshop proceedings, conclusions and paths forward for in vitro model use.
Behrsing H; Hill E; Raabe H; Tice R; Fitzpatrick S; Devlin R; Pinkerton K; Oberdörster G; Wright C; Wieczorek R; Aufderheide M; Steiner S; Krebs T; Asgharian B; Corley R; Oldham M; Adamson J; Li X; Rahman I; Grego S; Chu PH; McCullough S; Curren R
Altern Lab Anim; 2017 Jul; 45(3):117-158. PubMed ID: 28816053
[TBL] [Abstract][Full Text] [Related]
5. Substantial Equivalence Standards in Tobacco Governance: Statutory Clarity and Regulatory Precedent for the FSPTCA.
Carpenter D; Connolly GN; Lempert LK
J Health Polit Policy Law; 2017 Aug; 42(4):607-644. PubMed ID: 27864349
[TBL] [Abstract][Full Text] [Related]
6. Tobacco company efforts to influence the Food and Drug Administration-commissioned Institute of Medicine report clearing the smoke: an analysis of documents released through litigation.
Tan CE; Kyriss T; Glantz SA
PLoS Med; 2013; 10(5):e1001450. PubMed ID: 23723740
[TBL] [Abstract][Full Text] [Related]
7. Vuse Solo e-cigarettes do not provide net benefits to public health: a scientific analysis of FDA's marketing authorisation.
Glantz S; Lempert LK
Tob Control; 2024 Mar; 33(e1):e108-e115. PubMed ID: 36764683
[TBL] [Abstract][Full Text] [Related]
8. Heated tobacco product regulation under US law and the FCTC.
Lempert LK; Glantz SA
Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
[TBL] [Abstract][Full Text] [Related]
9. Permissive nicotine regulation as a complement to traditional tobacco control.
Sumner W
BMC Public Health; 2005 Feb; 5():18. PubMed ID: 15730554
[TBL] [Abstract][Full Text] [Related]
10. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
Lempert LK; Bialous S; Glantz S
Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
[TBL] [Abstract][Full Text] [Related]
11. Impact of modified risk tobacco product claims on beliefs of US adults and adolescents.
El-Toukhy S; Baig SA; Jeong M; Byron MJ; Ribisl KM; Brewer NT
Tob Control; 2018 Nov; 27(Suppl 1):s62-s69. PubMed ID: 30158212
[TBL] [Abstract][Full Text] [Related]
12. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
13. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
14. Assessing modified risk tobacco and nicotine products: Description of the scientific framework and assessment of a closed modular electronic cigarette.
Murphy J; Gaca M; Lowe F; Minet E; Breheny D; Prasad K; Camacho O; Fearon IM; Liu C; Wright C; McAdam K; Proctor C
Regul Toxicol Pharmacol; 2017 Nov; 90():342-357. PubMed ID: 28954704
[TBL] [Abstract][Full Text] [Related]
15. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association.
Henningfield JE; Benowitz NL; Slade J; Houston TP; Davis RM; Deitchman SD
Tob Control; 1998; 7(3):281-93. PubMed ID: 9825424
[TBL] [Abstract][Full Text] [Related]
16. The importance of product definitions in US e-cigarette laws and regulations.
Lempert LK; Grana R; Glantz SA
Tob Control; 2016 Apr; 25(e1):e44-51. PubMed ID: 25512432
[TBL] [Abstract][Full Text] [Related]
17. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
18. The importance of harmful and potentially harmful constituents in the implementation of the 2009 US Family Smoking Prevention and Tobacco Control Act.
Solyst J
Drug Test Anal; 2023 Oct; 15(10):1198-1204. PubMed ID: 36094139
[TBL] [Abstract][Full Text] [Related]
19. Understanding the Tobacco Control Act: efforts by the US Food and Drug Administration to make tobacco-related morbidity and mortality part of the USA's past, not its future.
Husten CG; Deyton LR
Lancet; 2013 May; 381(9877):1570-80. PubMed ID: 23642698
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
